The present invention provides for a pharmaceutical composition comprising lenalidomide form A, a filler and a disintegrant and a superdisintegrant. The present invention further relates to a process for the preparation of said composition. The composition according to the invention may be used as medicament, particularly for the treatment of multiple myeloma and myeolodisplastic syndromes.
